A Phase 1 interventional study of Irinotecan liposome;oxaliplatin;5-FU(Fluorouracil Injection);LV(Calcium Folinate Injection) in Advanced Pancreatic Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies testing fluorouracil in Pancreatic Neoplasms — 11 open to participants now, 16 under way, 5 of them phase 3. Fluorouracil · Pancreatic Neoplasms.
Among the 84 studies testing fluorouracil in Pancreatic Neoplasms, this one is the 48th largest by enrollment of the 76 interventional ones that give a count, is one of 4 that started in 2021, is one of 12 in phase 1, and was the 73rd registered.
3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.
Browse Pancreatic Neoplasms studies →11 of the 84 studies testing fluorouracil in Pancreatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Hopital Foch · Sites in France
Ages 18–75
Du Juan · Sites in China
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 18–75
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–75
By country, each count listing its studies:
Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →
Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 55 · Phase 3 15 · Phase 4 1
First in 1995; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 55 across the 76 interventional studies. Of the 51 that completed or were terminated, 18 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 84 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
15 studies in Pancreatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd.: 8 open now, 8 under way, 4 of them phase 3. Of 5 finished, 0 (0%) have results posted.
Among the 15 studies in Pancreatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 12th largest by enrollment, is one of 2 that started in 2021, is one of 4 in phase 1, and was the 5th registered.
Jiangsu HengRui Medicine Co., Ltd.’s Pancreatic Neoplasms studies by the year they started, since 2018.
4 of the studies testing fluorouracil in Pancreatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04927780Phase 3Erasmus Medical CenterPerioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer | 2027-01 |
| NCT06217042Phase 3Fudan UniversityHR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer | 2027-03-30 |
| NCT06494514Du JuanNALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer | 2027-04-01 |
| NCT03977233UNC Lineberger Comprehensive Cancer CenterTumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies testing fluorouracil in Pancreatic Neoplasms, from their registry updates:
Among Jiangsu HengRui Medicine Co., Ltd.’s 15 in Pancreatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
To determine the safety and tolerability of irinotecan liposome in combination with oxaliplatin and 5-FU/LV in subjects with advanced pancreatic cancer who have not received prior systemic chemotherapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1)Previously received treatment with irinotecan-containing regimens; 2)Received concomitant medications containing strong inhibitors/strong inducers of or strong inhibitors of UGT1A1 within two weeks before enrollment; 3)Received the last anti-cancer treatment (including surgery, radiotherapy, etc.) within four weeks before enrollment; 4)Have received treatment with any other drug/device within four weeks before enrollment; 5)Enrolled in another clinical study at the same time unless it is an observational (non-interventional) clinical study or an interventional clinical study follow-up.
7.Having experienced an arteriovenous thrombotic event, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism, within one year before enrollment; 8.Patients with cardiac clinical symptoms or diseases that are not well controlled, such as: (1) Patients with class 2 and above cardiac failure; (2) unstable angina; (3) myocardial infarction that occurred within one year; (4) supraventricular or ventricular arrhythmia requiring treatment or intervention.
9.Patients who have suffered from malignant tumors other than pancreatic cancer before using the study drug for the first time, except those with low risk of metastasis and death (5-year survival rate >90%), such as adequately treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin; 10.Have any to either irinotecan liposome, irinotecan, 5-FU, calcium folinate, or oxaliplatin;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1. irinotecan liposome: irinotecan liposome injection is irinotecan encapsulated in liposomes for i.v. infusion. 2. oxaliplatin: oxaliplatin is a sterile, aqueous solution; 50mg/vial. 3. 5-FU(Fluorouracil Injection): an aqueous, sterile, nonpyrogenic injectable solution available in 10ml/0.25g. 4. LV(Calcium Folinate Injection): be supplied in vials containing 10ml/0.1g and available as an injectable solution.
Drug: Irinotecan liposome;oxaliplatin;5-FU(Fluorouracil Injection);LV(Calcium Folinate Injection)
irinotecan liposome in combination with oxaliplatin and 5-FU/LV
MTD
Maximum tolerated dose for patients in combination treatment.
Time frame: 18 months
RP2D
Recommended phase II dose for patients in combination treatment.
Time frame: 18 months
Frequency and severity of AEs/SAEs as Assessed by CTCAE v5.0
Through laboratory test, physical examination, vital signs,12-lead electrocardiogram (ECG), Echocardiogram, etc.;
Time frame: From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.
Objective Response Rate (ORR)
Number of reported responses (complete \[CR\] and partial \[PR\]) divided by the number of reported assessable patients.
Time frame: From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.
Disease Control Rate (DCR)
Based on investigator reviewed radiographic tumour assessment and death.
Time frame: From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months
Duration of Response (DoR)
Based on investigator reviewed radiographic tumour assessment and death.
Time frame: From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.
Progression-Free Survival (PFS)
Based on change in tumour per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1
Time frame: From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.
Overall Survival (OS)
Based on investigator reviewed radiographic tumor assessment and death.
Time frame: From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.
Cmax
peak plasma concentration
Time frame: 28days
Tmax
time to peak concentration
Time frame: 28days
AUC
area under the plasma concentration versus time curve
Time frame: 28days
t1/2z
elimination half-life
Time frame: 28days
Vss
steady-state apparent volume of distribution
Time frame: 28days
CL
clearance
Time frame: 28days
Ran from Apr 2021 to primary completion in Jun 2024, 38 months.
Of 172 industry-sponsored phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 62. This study's 38 months is below that.
Counting every sponsor, half of 381 studies reached it within 45 months; a quarter within 32 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluorouracil
Jiangsu HengRui Medicine Co., Ltd. →